Abstract: The present invention provides a recombinant nucleic acid comprising: a first nucleic acid sequence encoding a 5? alphavirus replication recognition sequence; at least one second nucleic acid sequence encoding an alphavirus nonstructural protein; at least one alphavirus subgenomic promoter; at least one IRES element; at least one heterologous nucleic acid; and a third nucleic acid encoding a 3? alphavirus replication recognition sequence. Further provided are methods of making alphavirus particles comprising a recombinant nucleic acid of this invention and methods of using the compositions of this invention. Also provided is a recombinant helper nucleic acid comprising: a first nucleic acid sequence encoding a 5? alphavirus replication recognition sequence; an alphavirus subgenomic promoter; an IRES element; a second nucleic acid encoding an alphavirus structural protein; and a third nucleic acid encoding a 3? alphavirus replication recognition sequence.
Type:
Grant
Filed:
March 19, 2004
Date of Patent:
October 28, 2008
Assignee:
AlphaVax, Inc.
Inventors:
Jonathan F. Smith, Kurt I. Kamrud, Jon O. Rayner
Abstract: The present invention provides compositions useful in and methods for producing populations of infectious, replication-defective alphavirus replicon particles that contain no replication competent alphavirus particles, as determined by passage on cells in culture. The compositions include helper and replicon nucleic acid molecules that can further reduce the predicted frequency for formation of replication-competent virus and can optimize manufacturing strategies and costs.
Type:
Grant
Filed:
March 16, 2006
Date of Patent:
September 16, 2008
Assignee:
AlphaVax, Inc.
Inventors:
Jonathan F. Smith, Kurt I. Kamrud, Jonathan O. Rayner, Sergey A. Dryga, Ian J. Caley
Abstract: Provided herein are methods for producing alphavirus replicon particles in high yield; replicon RNAs are electroporated into permissive cells, where the cells are at a relatively high density, together with at least one helper nucleic acid providing the necessary functions for packaging. After a growth period in appropriate medium, alphavirus replicon particles are harvested from the surfaces of the cells in which they were produced using a salt wash in which the salt concentration is from about 0.2 to about 5 M sodium chloride, calcium chloride, magnesium chloride, potassium chloride, ammonium acetate, ammonium bicarbonate, among others. After dilution, if necessary, the particles can be purified by a suitable chromatographic technique.
Type:
Grant
Filed:
December 12, 2003
Date of Patent:
July 18, 2006
Assignee:
AlphaVax, Inc.
Inventors:
Jonathan F. Smith, Kurt Kamrud, Sergey Dryga, Harold Alterson, Jon Rayner, Kim Butler, Maureen F. Maughan
Abstract: The present invention provides compositions useful in and methods for producing populations of infectious, replication-defective alphavirus replicon particles that contain no replication-competent alphavirus particles, as determined by passage on cells in culture. The compositions include helper and replicon nucleic acid molecules that can further reduce the predicted frequency for formation of replication-competent virus and can optimize manufacturing strategies and costs.
Type:
Grant
Filed:
September 6, 2002
Date of Patent:
May 16, 2006
Assignee:
Alphavax, Inc.
Inventors:
Jonathan F. Smith, Kurt I. Kamrud, Jonathan O. Rayner, Sergey A. Dryga, Ian J. Caley
Abstract: The present disclosure provides TC-83 VEE-derived replicons, alphaviral replicon particles and immunogenic compositions containing TC-83 alphaviral replicon particles which direct the expression of at least one antigen when introduced into a suitable host cell. The TC-83 VEE-derived ARPs described herein are improved in that they are subject to a lower vector-specific immune response than prior art ARPs.
Type:
Application
Filed:
May 18, 2005
Publication date:
December 1, 2005
Applicant:
Alphavax, Inc.
Inventors:
Jon Rayner, Jonathan Smith, Bolyn Hubby, Elizabeth Reap
Abstract: The present invention provides methods and compositions comprising a population of alphavirus replicon particles comprising two or more isolated nucleic acids selected from 1) an isolated nucleic acid encoding an env gene product or an immunogenic fragment thereof of a human immunodeficiency virus, 2) an isolated nucleic acid encoding a g&agr;g gene product or an immunogenic fragment thereof of a human immunodeficiency virus, wherein the g&agr;g gene product or immunogenic fragment thereof is modified to inhibit formation of virus-like particles containing the g&agr;g gene product or the immunogenic fragment thereof and their release from a cell, and 3) an isolated nucleic acid encoding a pol gene product or an immunogenic fragment thereof of a human immunodeficiency virus, wherein the pol gene product or immunogenic fragment thereof is modified to inhibit protease, integrase, RNase H and/or reverse transcriptase activity, and wherein the nucleic acids are each contained within a separate alphavirus replicon
Type:
Grant
Filed:
November 16, 2001
Date of Patent:
August 31, 2004
Assignees:
Alphavax, Inc., University of North Carolina at Chapel Hill
Inventors:
Robert Olmsted, Paula Keith, Sergey Dryga, Ian Caley, Maureen Maughan, Robert Johnston, Nancy Davis, Ronald Swanstrom
Abstract: The present invention provides methods and compositions comprising a population of alphavirus replicon particles comprising two or more isolated nucleic acids selected from 1) an isolated nucleic acid encoding an env gene product or an immunogenic fragment thereof of a human immunodeficiency virus, 2) an isolated nucleic acid encoding a gag gene product or an immunogenic fragment thereof of a human immunodeficiency virus, wherein the gag gene product or immunogenic fragment thereof is modified to inhibit formation of virus-like particles containing the gag gene product or the immunogenic fragment thereof and their release from a cell, and 3) an isolated nucleic acid encoding a pol gene product or an immunogenic fragment thereof of a human immunodeficiency virus, wherein the pol gene product or immunogenic fragment thereof is modified to inhibit protease, integrase, RNase H and/or reverse transcriptase activity, and wherein the nucleic acids are each contained within a separate alphavirus replicon particle.
Type:
Application
Filed:
November 16, 2001
Publication date:
October 3, 2002
Applicant:
AlphaVax, Inc.
Inventors:
Robert Olmsted, Paula Keith, Sergey Dryga, Ian Caley, Maureen Maughan, Robert Johnston, Nancy Davis, Ronald Swanstrom